<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03624673</url>
  </required_header>
  <id_info>
    <org_study_id>ERASE Protocol v1.0 20180806</org_study_id>
    <nct_id>NCT03624673</nct_id>
  </id_info>
  <brief_title>Endoscopic Robot-Assisted Simple Enucleation Versus Standard Robot-Assisted Partial Nephrectomy in the Treatment of T1 Renal Cell Carcinoma</brief_title>
  <official_title>Endoscopic Robot-Assisted Simple Enucleation Versus Standard Robot-Assisted Partial Nephrectomy in the Treatment of T1 Renal Cell Carcinoma: A Non-inferiority Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-inferiority, randomized controlled trial to compare the peri-operative, renal
      functional and oncologic outcomes of endoscopic robot-assisted simple enucleation(ERASE) and
      standard robot-assisted partial nephrectomy(RAPN) in the treatment of T1 renal cell
      carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Simple enucleation (SE) consists of excising the tumor by blunt dissection following the
      natural cleavage plane between the peritumoral capsule and the renal parenchyma without
      removing a visible rim of healthy renal tissue, which appears to reserve more renal
      parenchyma without compromising oncologic safety, may be an alternative to standard partial
      nephrectomy (PN). Although published studies showed excellent long-term oncologic results,
      many urologists still consider SE an unsafe technique with a high risk of incomplete tumor
      excision. The aim of this study is to compare the peri-operative, renal functional and
      oncologic outcomes of endoscopic robot-assisted simple enucleation(ERASE) and standard
      robot-assisted partial nephrectomy(RAPN) in the treatment of T1 renal cell carcinoma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2018</start_date>
  <completion_date type="Anticipated">October 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rates of positive surgical margin</measure>
    <time_frame>10 days post surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>5-year Progression-free survival</measure>
    <time_frame>5 to 7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>absolute change in estimated glomerular filtration rate(eGFR)</measure>
    <time_frame>baseline, 3 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>absolute change in glomerular filtration rate (GFR) of the affected kidney measured by renal scintigraphy</measure>
    <time_frame>baseline, 3 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood loss</measure>
    <time_frame>during surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>operation time</measure>
    <time_frame>during surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>warm ischemic time</measure>
    <time_frame>during surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hilar clamping, entry into sinus, suturing tumor bed</measure>
    <time_frame>during surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intraoperative and postoperative complications</measure>
    <time_frame>up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>endoscopic robot-assisted simple enucleation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simple enucleation consists of excising the tumor by blunt dissection following the natural cleavage plane between the peritumoral capsule and the renal parenchyma without removing a visible rim of healthy renal tissue.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard robot-assisted partial nephrectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard partial nephrectomy is defined as the excision of the tumor and of an additional margin of healthy peritumor renal parenchyma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>endoscopic robot-assisted simple enucleation</intervention_name>
    <description>Simple enucleation consists of excising the tumor by blunt dissection following the natural cleavage plane between the peritumoral capsule and the renal parenchyma without removing a visible rim of healthy renal tissue.</description>
    <arm_group_label>endoscopic robot-assisted simple enucleation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>standard robot-assisted partial nephrectomy</intervention_name>
    <description>Standard partial nephrectomy is defined as the excision of the tumor and of an additional margin of healthy peritumor renal parenchyma.</description>
    <arm_group_label>standard robot-assisted partial nephrectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. patients with sporadic, unilateral, newly diagnosed T1 presumed renal cell carcinoma

          2. ECOG score &lt;=1

          3. RENAL score &lt;=9

          4. patients with normal contralateral renal function

          5. patients giving consent to the participation in the current clinical trial

        Exclusion Criteria:

          1. intolerance of robotic surgery

          2. metastastic renal cell carcinoma

          3. RENAL score &gt;=10

          4. entry into collection system or hematuria

          5. patients with a history of other renal diseases, such as urinary lithiasis

          6. patients with a history of renal surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongqian Guo, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hongqian Guo, PhD</last_name>
    <phone>8613605171690</phone>
    <email>dr.ghq@nju.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaozhi Zhao, PhD</last_name>
    <phone>8613851474779</phone>
    <email>dr.zxz@hotmail.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongqian Guo, MD</last_name>
      <phone>8613605171690</phone>
      <email>dr.ghq@nju.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Xiaozhi Zhao, MD</last_name>
      <phone>8613851474779</phone>
      <email>dr.zxz@hotmail.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 7, 2018</study_first_submitted>
  <study_first_submitted_qc>August 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2018</study_first_posted>
  <last_update_submitted>December 26, 2019</last_update_submitted>
  <last_update_submitted_qc>December 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</investigator_affiliation>
    <investigator_full_name>Hongqian Guo</investigator_full_name>
    <investigator_title>Executive officer of Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

